QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
NASDAQ:NCNA

NuCana (NCNA) Stock Forecast, Price & News

$0.62
-0.03 (-4.62%)
(As of 09/21/2023 ET)
Compare
Today's Range
$0.60
▼
$0.65
50-Day Range
$0.61
▼
$0.85
52-Week Range
$0.59
▼
$1.75
Volume
23,178 shs
Average Volume
84,223 shs
Market Capitalization
$32.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.75
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

NuCana MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
504.8% Upside
$3.75 Price Target
Short Interest
Healthy
0.13% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.64mentions of NuCana in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.58) to ($0.39) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.39 out of 5 stars

Medical Sector

218th out of 961 stocks

Pharmaceutical Preparations Industry

93rd out of 448 stocks

See Top Rated MarketRank™ Stocks Here

NCNA stock logo

About NuCana (NASDAQ:NCNA) Stock

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. The company applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing medicines, ProTides, to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil, which is in a Phase 1b/2 study in patients with metastatic colorectal cancer. The company also initiated a randomized Phase 2 study of NUC-3373, in combination with other agents, for the second-line treatment of patients with advanced colorectal cancer; and initiated a Phase 1b/2 modular study of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer. Its pipeline also comprises NUC-7738, a transformation of 3'-deoxyadenosine that is in the Phase 2 part of a Phase 1/2 study in patients with advanced solid tumors which is evaluating NUC-7738 as a monotherapy and in combination with pembrolizumab. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

NCNA Price History

NCNA Stock News Headlines

September 18, 2023 | finanznachrichten.de
NuCana plc: NuCana Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023
September 18, 2023 | finance.yahoo.com
NuCana Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023
September 21, 2023 | Behind the Markets (Ad)
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
September 7, 2023 | msn.com
Truist Securities Reiterates NuCana plc - ADR (NCNA) Buy Recommendation
August 17, 2023 | msn.com
European Equities Traded in the US as American Depositary Receipts Rise Again Thursday
August 17, 2023 | msn.com
NuCana Q2 Earnings: Recent Updates Bode Poorly, Not Worth The Risk
August 16, 2023 | finanznachrichten.de
NuCana plc: NuCana Reports Second Quarter 2023 Financial Results and Provides Business Update
August 16, 2023 | finance.yahoo.com
NuCana Reports Second Quarter 2023 Financial Results and Provides Business Update
September 21, 2023 | Chaikin Analytics (Ad)
Get Your Cash Out of U.S. Banks Immediately
Man who predicted 2023 bank run warns a historic financial reset is coming. Get out of cash and into a new vehicle 50 years in the making. Click here to learn more.
August 9, 2023 | msn.com
European Equities Traded in the US as American Depositary Receipts Trend Lower Wednesday
July 25, 2023 | msn.com
European Equities Traded in the US as American Depositary Receipts Rise Tuesday
July 24, 2023 | msn.com
European Equities Traded in the US as American Depositary Receipts Start Week Moving Lower
July 10, 2023 | msn.com
European Equities Traded in the US as American Depositary Receipts Open Week Higher
July 6, 2023 | msn.com
European Equities Traded in the US as American Depositary Receipts Tumble Thursday
July 3, 2023 | msn.com
European Equities Traded in the US as American Depositary Receipts Start Week Off Lower Monday
June 1, 2023 | finanznachrichten.de
NuCana plc: NuCana to Present at the Jefferies Healthcare Conference
June 1, 2023 | finance.yahoo.com
NuCana to Present at the Jefferies Healthcare Conference
May 22, 2023 | msn.com
Oppenheimer Reiterates NuCana plc - ADR (NCNA) Outperform Recommendation
May 17, 2023 | finanznachrichten.de
NuCana plc: NuCana Reports First Quarter 2023 Financial Results and Provides Business Update
May 17, 2023 | finance.yahoo.com
NuCana Reports First Quarter 2023 Financial Results and Provides Business Update
May 14, 2023 | marketwatch.com
NuCana Receives Notices That ADSs Don't Satisfy Nasdaq Listing Requirements
April 15, 2023 | finanznachrichten.de
NuCana plc: NuCana Presents Data at the AACR 2023 Annual Meeting Highlighting Novel NUC-7738 Mechanisms of Action
April 14, 2023 | finance.yahoo.com
NuCana Presents Data at the AACR 2023 Annual Meeting Highlighting Novel NUC-7738 Mechanisms of Action
April 4, 2023 | finance.yahoo.com
NuCana Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update
March 24, 2023 | finance.yahoo.com
Technical Board of Appeal of the European Patent Office Issues Oral Ruling that NuCana’s ‘190 Patent is Not Valid
March 24, 2023 | finance.yahoo.com
We're Keeping An Eye On NuCana's (NASDAQ:NCNA) Cash Burn Rate
March 14, 2023 | msn.com
Bank Stocks Boost European Equities Sharply Higher in Tuesday Trading
See More Headlines
Receive NCNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NuCana and its competitors with MarketBeat's FREE daily newsletter.

NCNA Company Calendar

Last Earnings
8/16/2023
Today
9/21/2023
Next Earnings (Estimated)
11/15/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NCNA
CUSIP
N/A
CIK
1709626
Web
www.nucana.com
Phone
441313571111
Fax
N/A
Employees
28
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.75
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+504.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.76)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-39,610,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-86.57%
Return on Assets
-59.91%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.80
Quick Ratio
2.80

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.91 per share
Price / Book
0.68

Miscellaneous

Outstanding Shares
51,900,000
Free Float
35,709,000
Market Cap
$32.18 million
Optionable
Not Optionable
Beta
1.15
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Hugh Stephen Griffith (Age 55)
    Founder, CEO & Exec. Director
    Comp: $1.27M
  • Mr. Donald Munoz (Age 54)
    Chief Financial Officer
  • Mr. David Harrison (Age 64)
    Head of Translational Medicine
  • Prof. Christopher B. Wood FRCS (Age 77)
    M.D., Ph.D., Chief Medical Officer
  • Ms. Theresa Bruce
    Sr. VP of Clinical Operations
  • Ms. Elisabeth Oelmann
    Sr. VP of Medical & Clinical Devel.
  • Dr. Jeffrey D. Bloss F.A.C.O.G. (Age 66)
    M.D., Chief Medical Officer
  • Martin Quinn
    Company Sec.

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













NCNA Stock - Frequently Asked Questions

Should I buy or sell NuCana stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NuCana in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NCNA shares.
View NCNA analyst ratings or view top-rated stocks.

What is NuCana's stock price forecast for 2023?

3 brokerages have issued twelve-month target prices for NuCana's stock. Their NCNA share price forecasts range from $2.00 to $6.00. On average, they anticipate the company's stock price to reach $3.75 in the next year. This suggests a possible upside of 504.8% from the stock's current price.
View analysts price targets for NCNA or view top-rated stocks among Wall Street analysts.

How have NCNA shares performed in 2023?

NuCana's stock was trading at $0.66 on January 1st, 2023. Since then, NCNA stock has decreased by 6.1% and is now trading at $0.62.
View the best growth stocks for 2023 here.

Are investors shorting NuCana?

NuCana saw a decline in short interest in August. As of August 31st, there was short interest totaling 55,100 shares, a decline of 45.5% from the August 15th total of 101,100 shares. Based on an average daily trading volume, of 49,300 shares, the days-to-cover ratio is presently 1.1 days. Currently, 0.1% of the company's shares are short sold.
View NuCana's Short Interest.

When is NuCana's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 15th 2023.
View our NCNA earnings forecast.

How were NuCana's earnings last quarter?

NuCana plc (NASDAQ:NCNA) announced its quarterly earnings results on Wednesday, August, 16th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.03.

What other stocks do shareholders of NuCana own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NuCana investors own include Wirecard (WDI), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Ovid Therapeutics (OVID), SCYNEXIS (SCYX), Aldeyra Therapeutics (ALDX), Allena Pharmaceuticals (ALNA), Pfizer (PFE), Rigel Pharmaceuticals (RIGL) and Tetraphase Pharmaceuticals (TTPH).

When did NuCana IPO?

(NCNA) raised $100 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Citigroup, Jefferies and Cowen served as the underwriters for the IPO and William Blair was co-manager.

What is NuCana's stock symbol?

NuCana trades on the NASDAQ under the ticker symbol "NCNA."

Who are NuCana's major shareholders?

NuCana's stock is owned by a variety of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.71%).

How do I buy shares of NuCana?

Shares of NCNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NuCana's stock price today?

One share of NCNA stock can currently be purchased for approximately $0.62.

How much money does NuCana make?

NuCana (NASDAQ:NCNA) has a market capitalization of $32.18 million. The company earns $-39,610,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis.

How can I contact NuCana?

NuCana's mailing address is 3 Lochside Way, Edinburgh X0, EH12 9DT. The official website for the company is www.nucana.com. The company can be reached via phone at 441313571111 or via email at chris.brinzey@westwicke.com.

This page (NASDAQ:NCNA) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -